Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by GSA Capital Partners LLP

GSA Capital Partners LLP boosted its position in Athira Pharma, Inc. (NASDAQ:ATHA) by 909.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 397,111 shares of the company’s stock after purchasing an additional 357,787 shares during the period. GSA Capital Partners LLP owned approximately 1.03% of Athira Pharma worth $177,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bristlecone Advisors LLC lifted its holdings in shares of Athira Pharma by 295.6% in the third quarter. Bristlecone Advisors LLC now owns 337,506 shares of the company’s stock valued at $151,000 after buying an additional 252,200 shares during the period. Invst LLC acquired a new stake in Athira Pharma during the second quarter valued at approximately $68,000. Forefront Analytics LLC grew its holdings in shares of Athira Pharma by 126.0% in the 2nd quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock worth $123,000 after acquiring an additional 25,979 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Athira Pharma during the second quarter worth $60,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Athira Pharma by 3.5% during the second quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock valued at $719,000 after purchasing an additional 9,164 shares during the last quarter. 57.12% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ATHA shares. Rodman & Renshaw lowered shares of Athira Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, September 4th. BTIG Research cut shares of Athira Pharma from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 4th. JMP Securities lowered Athira Pharma from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 4th. Finally, Mizuho downgraded Athira Pharma from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $5.00 to $0.50 in a research report on Thursday, September 19th.

Athira Pharma Price Performance

Shares of Athira Pharma stock opened at $0.64 on Monday. The firm has a market capitalization of $24.83 million, a PE ratio of -0.23 and a beta of 2.82. The company’s fifty day moving average price is $0.52 and its two-hundred day moving average price is $1.90. Athira Pharma, Inc. has a 52-week low of $0.41 and a 52-week high of $4.30.

Athira Pharma (NASDAQ:ATHA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.05. Analysts predict that Athira Pharma, Inc. will post -2.35 earnings per share for the current fiscal year.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.